MedPath

Quantum BioPharma's UnbuzzdTM Shows 40% Faster Alcohol Metabolism in Clinical Trial

• Clinical trial demonstrates UnbuzzdTM dietary supplement accelerates alcohol metabolism by 40% within 30 minutes compared to placebo, while improving alertness and stabilizing vital signs.

• Study participants reported reduced mental fatigue and hangover symptoms without experiencing adverse side effects, marking a significant advancement in alcohol consumption management.

• Quantum BioPharma maintains pharmaceutical development rights while partnering with Celly Nutrition for over-the-counter distribution, securing ongoing royalties up to $250 million.

In a significant advancement for alcohol metabolism management, Quantum BioPharma (NASDAQ: QNTM) has announced positive results from a recently completed clinical trial for its dietary supplement UnbuzzdTM. The study demonstrated remarkable efficacy in accelerating alcohol metabolism and reducing intoxication symptoms.

Clinical Trial Results

The double-blind, placebo-controlled study revealed that UnbuzzdTM significantly enhanced alcohol metabolism, reducing blood alcohol concentration by more than 40% within 30 minutes compared to placebo. Beyond alcohol metabolism, the supplement showed additional beneficial effects, including improved alertness and stabilization of cardiovascular parameters such as heart rate and blood pressure.
"UnbuzzdTM represents a breakthrough in promoting safe and responsible alcohol consumption," stated Quantum BioPharma CEO Zeeshan Saeed. The trial participants reported notable improvements in common alcohol-related issues, experiencing reduced mental fatigue and decreased hangover symptoms, with no observed adverse effects.

Strategic Commercial Partnership

While maintaining its focus on pharmaceutical development, Quantum BioPharma has established a strategic partnership with Celly Nutrition Corp. for the over-the-counter distribution of UnbuzzdTM. The agreement includes a 7% royalty on sales until reaching $250 million in payments to Quantum BioPharma, after which it converts to a 3% perpetual royalty. Notably, Quantum BioPharma retains a 25.71% ownership stake in Celly Nutrition and maintains exclusive rights for pharmaceutical and medical applications of similar products.

Broader Corporate Focus

Beyond UnbuzzdTM, Quantum BioPharma continues to advance its neurodegenerative disease portfolio through its subsidiary, Lucid Psycheceuticals Inc. The company's lead compound, Lucid-MS, has shown promise in preclinical models for multiple sclerosis treatment by preventing and reversing myelin degradation, demonstrating the company's commitment to addressing various medical challenges.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Qlaris Reports Positive Phase II Results for QLS-111 in Reducing Intraocular Pressure

Qlaris Bio's investigational drug QLS-111 demonstrated significant reduction in intraocular pressure across two Phase II clinical trials, marking a potential advancement in glaucoma treatment.
The clinical trials evaluated QLS-111's safety and efficacy in patients with elevated intraocular pressure, showing promising results in meeting primary endpoints.

BRAIN.Q Achieves CE Mark for Breakthrough Therapy in Reducing Post-Stroke Disability

BRAIN.Q has received the CE mark for its BQ 2.0 system, a non-invasive, AI-powered therapy aimed at reducing disability following an ischaemic stroke, marking a significant advancement in stroke recovery treatments.

Quoin Pharmaceuticals' QRX003 Shows Promise in Netherton Syndrome Trial

Quoin Pharmaceuticals' QRX003 demonstrates significant symptom reduction in a Netherton Syndrome clinical trial, with an 83% improvement observed in the first subject after 12 weeks.
The open-label study showed improvements across multiple clinical endpoints, including M-IASI, WINRS, and IGA, with no reported safety concerns and high patient satisfaction.

First-In-Human Trial of TherVacB Hepatitis B Vaccine Shows Promise

TherVacB, a novel therapeutic vaccine, has entered its first in-human clinical trial, offering potential for a hepatitis B cure.
The vaccine aims to activate CD4 T-cells, addressing the global impact of chronic hepatitis B, which affects over 300 million people.

Quantum BioPharma Advances Lucid-21-302 Clinical Trial for Multiple Sclerosis

Quantum BioPharma's Lucid-21-302, a potential treatment for multiple sclerosis, has progressed to the second cohort dosing phase after positive safety review.
The Phase 1 trial evaluates the safety and pharmacokinetics of Lucid-21-302 in healthy adults, with dosing for the next group expected to begin shortly.

Major Milestone for UQ Spin-Out's Promising MND Drug

A new treatment for motor neurone disease (MND) developed by NuNerve, a company spun-out from The University of Queensland, has shown promising results in a Phase 1 clinical trial. The drug, NUN-004, was found to be safe and effective, offering hope for slowing disease progression and improving motor movement in patients.

Sunshine Biopharma's K1.1 mRNA Shows Promise in Treating Liver Cancer in Preclinical Studies

Sunshine Biopharma's K1.1 mRNA demonstrated dose-dependent anti-proliferative activity against human hepatocellular carcinoma (HCC) cells in vitro.
In vivo studies showed that K1.1 mRNA, encapsulated in lipid nanoparticles (K1.1/LNP), effectively reduced the growth of HCC tumors in mice.

Quince Therapeutics' EryDex Phase 3 Trial for Ataxia-Telangiectasia Nears Enrollment Completion

Quince Therapeutics' Phase 3 NEAT trial of EryDex for Ataxia-Telangiectasia (A-T) is expected to complete enrollment in Q2 2025, marking a significant milestone.
Topline results from the international, multi-center NEAT trial, evaluating EryDex's neurological effects in A-T patients, are anticipated in Q4 2025.

Vanqua Bio's VQ-101 Shows Promise in Parkinson's Disease with Phase Ib Trial Initiation

Vanqua Bio's VQ-101, an oral small molecule, demonstrated over 75% activation of GCase in healthy volunteers, surpassing the target engagement goal in a Phase Ia trial.
The Phase Ia trial showed VQ-101 to be well-tolerated, with no dose-limiting or serious adverse events, and achieved significant CNS penetration.

Ascentage Pharma Announces Milestone Payment from UNITY Biotechnology for Senolytic Drug Candidate UBX1325

Ascentage Pharma has announced a milestone payment from UNITY Biotechnology following encouraging Phase I clinical study results for UBX1325, a senolytic drug candidate targeting advanced vascular eye diseases. The drug, developed from Ascentage Pharma's licensed compound BM-962, has shown rapid improvement in patients with diabetic macular edema or wet age-related macular degeneration, leading to the initiation of a Phase IIa clinical study.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy